Detailed data from the Phase 1 first-in-human study of BRB-002 will be presented at the American College of Cardiology Scientific Session in March 2025. A Phase 2 proof-of-concept trial of BRB-002 in ...

Clinically, patients with the disease may have a relatively benign course, with mild purpura secondary to thrombocytopenia, or may have progressive hepatic cirrhosis, hepatic failure and death.

Thrombocytopenia typically occurs 1 to 2 weeks after administration. In rare cases, obinutuzumab can induce severe acute thrombocytopenia within days of infusion, a condition known as ...

Rilzabrutinib may be a promising and effective therapy for patients with primary immune thrombocytopenia (ITP) who are unresponsive or intolerant to standard therapies, according to pivotal results ...

BTK, expressed in B cells, macrophages, and other immune cells ... including immune thrombocytopenia, warm autoimmune hemolytic anemia (phase 2), asthma (phase 2), chronic spontaneous urticaria ...